1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Jetema Co., Ltd.

Jetema Co., Ltd.

KKRX:216080
6,050.00
KRW
+100.00
(+1.68%)
-53.05EPS
184.74BMarket Cap
Nov 18Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
424.81
385.98
509.45
256.53
599.17
940.14
1,296.04
1,646.41
909.95
2,143.07
2,102.31
Basic EPS, GAAP
27.51
-263.75
-716
-284
-270.5
308
41
391.61
-2.5
-184
-36.54
Free Cash Flow per Basic Share
25.77
-486.72
-845.74
-406.09
-49.52
-286.15
-1,403.74
-9.19
-67.43
-133.74
-212.28
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
179.38
127.39
-169.64
1,045.01
1,183.04
1,535.56
1,598.43
2,002.16
2,019.99
1,759.21
2,193.91
Tangible Book Value per Share
178.9
126.71
-170.21
1,042.2
1,176.54
1,525.47
1,527.94
1,748.29
1,556.93
1,097.26
1,490.2
Basic Weighted Avg Shares
30
21
22
52
34
35
35
36
75
36
36
Sales/Revenue/Turnover
12,632
8,171
11,208
13,300
20,660
33,223
45,994
58,716
68,520
76,903
76,583
Operating Margin (%)
16.52
-49.02
-40.61
-80.71
-27.04
6.86
8.71
4.49
6
4.97
5
Depreciation Expense
641
805
927
1,612
3,077
3,368
5,114
8,374
9,102
8,559
8,424
Net Income, GAAP
818
-5,583
-15,752
-14,724
-9,327
10,884
1,455
13,966
-188
-6,603
-1,331
Effective Tax Rate (%)
18.32
- -
- -
- -
- -
- -
22.78
- -
- -
- -
- -
Profit Margin (%)
6.48
-68.33
-140.54
-110.71
-45.15
32.76
3.16
23.79
-0.27
-8.59
-1.74
Working Capital
10,598
-3,627
-27,480
-346
11,366
64,381
-26,172
-23,590
-89,221
-52,459
-17,776
LT Debt
8,851
4,715
6,858
5,621
3,973
48,012
61,712
60,452
398
50,470
69,915
Total Equity
5,334
3,788
-5,045
33,938
41,564
54,562
56,947
73,056
71,428
65,002
80,710
Return on Invested Capital (%)
- -
- -
- -
- -
- -
2.73
2.25
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
17.2
6.41
- -
- -
- -
- -
Return on Common Equity (%)
- -
-122.41
- -
- -
-24.71
22.65
2.61
21.74
-0.26
-9.59
-1.8

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
66,685
61,708
63,220
LT Borrowings
50,100
54,100
69,594
LT Finance Leases
370
355
321
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
37
37
Market Capitalization
227,720
278,324
184,743

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
31,298
32,435
65,285
Cash, Cash Equivalents & STI
5,225
5,693
37,809
Accounts Receivable, Net
5,214
4,926
6,833
Inventories
17,081
17,316
17,628
Total Current Liabilities
83,757
76,109
83,061
Payables & Accruals
- -
- -
- -
ST Debt
66,685
61,708
63,220
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
10.54%
-9%
Free Cash Flow
- -
445.89%
-5.48%
Net Income, GAAP
- -
772.51%
3,407.38%
Sales/Revenue/Turnover
- -
31.17%
12.23%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
17,226
17,306
14,962
19,026
68,520
2025
15,833
20,573
20,119
20,378
76,903
2026
16,004
20,082
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-19.5
-0.5
-46
126.29
-2.5
2025
-102.2
-60
-85.77
63.33
-184
2026
-58.29
42.83
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jeong Sun Nam
Full Time Employees
244
Sector
Health technology
Industry
Medical specialties
Address
1283-4, Gagok-ri Wonju-si GA South Korea
IPO Date
Nov 14, 2019
Website
jetema.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
JETEMA, Co., Ltd. engages in the research, development, manufacturing, and sale of biopharmaceuticals and medical devices focused on aesthetic medicine and anti-aging treatments. The company offers core products including botulinum toxins such as Jetema The Toxin, a next-generation clean toxin free from strain-related risks; hyaluronic acid dermal fillers under the e.p.t.q. brand with variants like S100, S300, and S500 lidocaine formulations for superficial lines, lip volumizing, nasolabial folds, deep folds, jawlines, and cheekbones; lifting threads branded epiticon with models such as Original (fixed-type dual-acting cogs), BI (bi-directional for contouring), Thin, and JAMBER (coiled collagen framework); anti-aging meso solutions under vitten including hydro, hydro plus, hair Rx, and hair daily for skin hydration, regeneration, and hair loss treatment; laser surgical instruments for leukoplakia, psoriasis, and alopecia areata; skin care hyaluronic acid masks; and cosmetics like e.p.t.q. By.derm intensive cream, centella cica plus masks, and plant exosome moisture mist. JETEMA operates primarily in the biotechnology and pharmaceuticals sector, targeting aesthetic clinics, medical professionals, and consumers in domestic and international markets including partnerships in China, Spain, and plans for the United States; founded in 2009, the company maintains headquarters in Wonju, South Korea, with manufacturing facilities in Wonju and Yongin-si, an R&D center in Seongnam-si, and approximately 235 employees. In recent developments, JETEMA commercialized Jetema The Toxin following domestic approval last year and advanced phase 3 clinical trials in China fully funded by partner Huadong Aesthetic, with completion expected in late 2025; phase 2 trials for the toxin proceed in the United States targeting approval this year; the company secured KRW 56 billion in funding via Series 9 convertible bonds in July 2023 from investors including Korea Investment Re-Up Fund II and Hantoo Shinhan Lake K-Beauty Fund to support expansion; and Spanish partner THR Medical Productos launched Ecolla filler through a seminar in 2025 focused on aging delay treatments.